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Facilitation of lethal ventricular arrhythmias by 
therapeutic digoxin in conscious post infarction 
dogs 
The proarrhythmic potential of digoxin, administered in a therapeutic dosage regimen, was 
evaluated in conscious dogs in the subacute phase of myocardial infarction. In this evaluation, 
digoxin (0.0125 mg/kg/day intravenously) or vehicle were administered to conscious dogs for 
periods of 5 to 7 days, commencing 4 to 5 days after anterior myocardial infarction. Before 
treatment, programmed ventricular stimulation failed to initiate ventricular tachycardia in 26 post 
infarction dogs. After treatment, programmed stimulation initiated ventricular tachyarrhythmias in 
only 1 of 13 digoxin-treated dogs (1.36 + 0.17 rig/ml serum digoxin) and in 0 of 13 
vehicle-treated dogs. However, the incidences of early ventricular fibrilatlion (4 of 10 digoxin vs 
0 of 12 vehicle; p < 0.05) and of 24-hour mortality (6 of 10 digoxin vs 2 of 12 vehicle; p < 0.05) 
occurring in response to the development of posterolateral ischemia in the presence of previous 
anterior myocardial infarction was significantly greater in digoxin-treated (1.47 f 0.19 rig/ml 
serum digoxin) than in vehicle-treated animals. These findings suggest an enhanced susceptibility 
toward the development of ischemia-related lethal arrhythmias in the presence of therapeutic 
digoxin serum concentrations early after myocardial infarction, which is not predicted by 
programmed ventricular stimulation testing. (AM HEART J 111:883, 1988.) 
Joseph J. Lynch, Ph.D., Daniel G. Montgomery, B.S., 
and Benedict R. Lucchesi, Ph.D., M.D. Ann Arbor, Mich. 
Considerable uncertainty surrounds the use of digi- 
talis in patients with ischemic myocardial injury.‘,’ 
Several large nonrandomized clinical studies have 
attempted to evaluate the potential deleterious 
effects of digitalis therapy on survival after acute 
myocardial infarction, but have yielded conflicting 
and equivocal results.3-7 Experimental studies con- 
ducted to date suggest an enhanced myocardial 
sensitivity to the arrhythmogenic actions of digitalis 
preparations in the settings of myocardial ische- 
mia8-lo and/or myocardial infarction.8p g, 1*-15 However, 
all previous experimental studies invariably have 
employed the rapid administration of toxic concen- 
trations of digitalis preparations in assessing myo- 
cardial sensitivity,8-15 thereby limiting the relevance 
of conclusions drawn from such studies to the 
clinical situation. 
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Previous1y,*6 this laboratory has described a con- 
scious canine model for the study of sudden coro- 
nary death precipitated by the development of 
ischemia at a site distant from an area of previous 
myocardial infarction. More recent studies have 
demonstrated a predictive relationship between sus- 
ceptibility to the initiation of ventricular tachyar- 
rhythmias by programmed ventricular stimulation 
and vulnerability to the development of lethal ven- 
tricular arrhythmias in response to a subsequent 
ischemic episode in this conscious post infarction 
dog mode1.17 This relationship permits the identifi- 
cation of post infarction animals at low risk to the 
development of ischemia-related malignant ventric- 
ular arrhythmias via prior programmed ventricular 
stimulation testing.17 In the present investigation, 
post infarction dogs which were determined to be at 
a low risk for the development of ischemia-induced 
lethal arrhythmias were employed to evaluate the 
arrhythmogenic potential of the digitalis glycoside, 
digoxin, administered in a therapeutic dosing regi- 
men. 
METHODS 
Surgical preparation. Male mongrel dogs (14.0 to 19.0 
kg) were anesthetized with intravenous sodium pentobar- 
bital, 30 mg/kg. The dogs were ventilated with room air 
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Fig. 1. Conscious post infarction canine model. On the 
day of surgical preparation, anterior myocardial ischemic 
injury (demarcated by the broken line) was produced by a 
a-hour occlusion of the left anterior descending coronary 
artery, followed by reperfusion through a critical stenosis. 
An epicardial bipolar electrode (A) was sewn onto the left 
atria1 appendage for atria1 pacing, and a plunge bipolar 
electrode (B) was inserted into the interventricular sep- 
tum, adjacent to the site of occlusion, for the determina- 
tion of ventricular excitation threshold and refractory 
period, as well as for the delivery of programmed ventric- 
ular extrastimuli. Plunge bipolar electrodes were inserted 
into normal, noninjured myocardium (C) and into poten- 
tially infarcted myocardium (0) for the recording of local 
activation, and for the construction of ventricular 
strength-interval curves. The bared tip of an insulated 
silver wire (E) was inserted into the lumen of the left 
circumflex coronary artery, and the wire was sutured onto 
the surface of the heart. 
with the use of a cuffed endotracheal tube and a Harvard 
respirator. By the use of the aseptic technique, the left 
external jugular vein and left common carotid artery were 
isolated, and cannulas were inserted. A left thoracotomy 
was performed between the fourth and fifth ribs. The 
pericardium was opened and the heart was suspended in a 
pericardial cradle. The left anterior descending coronary 
artery was isolated at the tip of the left atria1 appendage, 
and the left circumflex coronary artery was isolated 
approximately 1 cm from its origin. A 19- or 20-gauge 
hypodermic needle was placed parallel to the left anterior 
descending coronary artery and a suture was passed 
around both the vessel and the needle. The suture was tied 
securely and the needle was withdrawn, producing a 
critical stenosis. The artery was then occluded using a 
snare formed from a loop of silicone rubber tubing passed 
through a polyethylene tube. Blood flow through the left 
anterior descending coronary artery was restored after 2 
hours. 
An epicardial bipolar electrode (1 mm diameter silver 
electrodes embedded 3 mm apart in acrylic) was sutured 
to the left atria1 appendage for atria1 pacing. A bipolar 
plunge electrode (25-gauge insulated stainless steel wire, 5 
mm in length, 2 mm apart) was sutured into the interven- 
tricular septum adjacent to the right ventricular outflow 
tract for the determination of ventricular excitation 
threshold, ventricular refractory period, and for the intro- 
duction of ventricular extrastimuli during programmed 
stimulation. Two short (2 to 3 mm) stainless steel bipolar 
plunge electrodes were used for the measurement of 
ventricular activation times and for the construction of 
ventricular strength-interval curves. One short bipolar 
electrode was implanted in the distribution of the left 
anterior descending coronary artery distal to the site of 
occlusion (IZ, infarct zone), while a second electrode was 
implanted in the left circumflex coronary artery distribu- 
tion (NZ, normal zone). A 3 mm section of bared insulated 
30-gauge silver wire was inserted through the wall and to 
the lumen of the left circumflex coronary artery and was 
sutured in place on the surface of the heart. Silver disc 
electrodes were implanted subcutaneously. The surgical 
incision was closed and the animals were allowed to 
recover from surgical anesthesia. The animals received 
ampicillin, 10 mg/kg subcutaneously twice daily, during 
their post infarction convalescence. The essential ex- 
perimental features of this preparation are illustrated in 
Fig. 1. 
Experimental protocol. Post infarction dogs were 
returned to the laboratory 4 to 5 days after surgical 
preparation. Electrophysiologic testing and programmed 
ventricular stimulation were performed while the animals 
were conscious, unsedated, and resting comfortably in a 
sling. Only post infarction dogs that were not susceptible 
to the initiation of ventricular tachycardia during initial 
programmed stimulation testing were entered into the 
present investigation. Previous work in this laboratory has 
shown that post infarction dogs that are resistant to the 
induction of ventricular tachycardia by programmed stim- 
ulation are at “low risk” toward the development of lethal 
ventricular arrhythmias in response to the subsequent 
development of posterolateral ischemia (i.e., ischemia at a 
site distant from the area of previous myocardial infarc- 
tion) .I7 
After initial electrophysiologic testing, post infarction 
dogs were randomized to treatment with either digoxin 
(n = 13,0.0125 mg/kg/day intravenous Lanoxin, adminis- 
tered in the afternoon as a single infusion via the jugular 
vein, for 5 to 7 consecutive days) or with vehicle (n = 13, 
digoxin diluent in matching volume, administered as a 
single afternoon infusion, for 5 to 7 consecutive days). 
Daily morning blood samples were obtained by peripheral 
venipuncture from the first six digoxin-treated animals for 
the characterization of the serum digoxin-time course 
profile. Morning venous blood samples were obtained 
from all digoxin and vehicle-treated animals for the 
determination of serum potassium and digoxin concentra- 
tions on the day of repeat electrophysiologic testing. 
After the appropriate treatment periods, digoxin- and 
vehicle-treated dogs were subjected to repeat electrophys- 
iologic study and programmed ventricular stimulation in 
the conscious, unsedated state. Immediately thereafter, 
digoxin-treated (n = 10) and vehicle-treated (n = 12) dogs 
were entered into the protocol for left circumflex (LCX) 
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coronary artery intimal injury. Technical failures associ- 
ated with the latter protocol (fractured or improperly 
positioned LCX wire, n = 3; two digoxin- and one vehicle- 
treated) and lethal responses to programmed stimulation 
(n = 1) account for the reduction in the number of animals 
entered into the protocol for LCX coronary artery inju- 
ry. 
Electrophysiologic studies and programmed electri- 
cal stimulation. Animals were studied while they were 
conscious, unsedated, and resting comfortably in a sling. 
ECG intervals and electrophysiologic parameters were 
determined immediately before programmed stimulation 
testing. ECG intervals were measured during sinus 
rhythm. A corrected QT interval (QT, = QT in msec/(R-R 
in sec)l12) was determined during sinus rhythm, while a 
paced QT interval was determined during atria1 pacing 
(2.5 Hz). Ventricular excitation thresholds, refractory 
periods, and activation times were determined during 
atria1 pacing (2.5 Hz). The ventricular excitation thresh- 
old was defined as the minimum voltage required to 
produce a conducted ventricular beat at a stimulus dura- 
tion of 4 msec delivered 300 msec after the R wave of the 
lead II ECG. The ventricular refractory period was the 
longest R-to-stimulus interval at which a 2x threshold 
stimulus (4 msec duration) failed to produce a conducted 
ventricular beat. Normal zone and infarct zone ventricular 
activation times, the intervals between the Q wave of the 
lead II ECG, and the largest deflection of the local 
ventricular electrograms (Q-EG), were measured on a 
Tektronix model 5111 oscilloscope. Ventricular strength- 
interval curves were constructed in normal and infarcted 
myocardium by a modification of a previously reported 
method.18 An extrastimulus (S,) is introduced in late 
diastole at a minimum milliamperage for eliciting a ven- 
tricular response (V,) during a basic V,-V, drive cycle 
length of 400 msec (heart rate of 150 bpm) in the conscious 
dog. The current for the drive beats is held constant 
throughout the determination at twice the minimum 
diastolic threshold for excitability. The coupling interval 
of S, is then decreased incrementally until S, fails to elicit 
a V,. When S, fails to elicit a VZ, the milliamperage of S, is 
increased until a V, is elicited, and the coupling interval is 
decreased until S, again fails to elicit a V,. This sequence 
is repeated until a ventricular effective refractory period 
(ERP) is reached at a maximum current of 4 mA. The 
ERP, therefore, is defined as the longest S,-S, interval 
that fails to elicit V, at 4 mA. The relative refractory 
period (RRP) is defined as the longest coupling interval 
along the strength-interval curve at which the current 
required to evoke a response (V,) increases above the 
diastolic excitability threshold (ET) by greater than 0.025 
mA for a 1 msec change in coupling interval.18 
During the programmed electrical stimulation protocol, 
premature ventricular stimuli (4 msec duration, 2x 
threshold) were introduced into the interventricular sep- 
tum using a Grass model S-88 stimulator and a Grass 
model SIU-5 stimulus isolation unit. Single (S,), double 
(S&S,), and then triple (S,-S&-S,) premature ventricular 
stimuli were introduced. Single ventricular extrastimuli 
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Fig. 2. Serum digoxin concentrations were determined 
daily for the first six digoxin-treated post infarction dogs 
(0.0125 mglkglday digoxin). Serum digoxin concentra- 
tions (mean t S.E.M.) are plotted as a function of treat- 
ment day during the treatment period. 
were introduced during atria1 pacing at S-S, coupling 
intervals decreasing from 350 msec until ventricular 
refractoriness occurred. Thereafter, double and triple 
ventricular extrastimuli were introduced during sinus 
rhythm at S,-S, and S&&-S, coupling intervals of 182,167, 
154,143,133, and 125 msec. Previous work has shown that 
this method fails to produce ventricular dysrhythmias in 
sham-operated animals without previous myocardial is- 
chemic injury.“j 
lschemia at a site remote from previous myocardial 
infarction: Left circumflex intimal stimulation and injury. 
After the completion of post treatment programmed 
ventricular stimulation testing, an anodal direct current of 
150 PA was applied to the intimal surface of the left 
circumflex coronary artery uia the previously inserted 
silver wire electrode. The lead II ECG was recorded 
directly onto a Grass polygraph or was recorded, at preset 
intervals, by a programmable cardiocassette recorder. 
Upon completion of the experiment at 24 hours of 
electrical stimulation or upon the development of ventric- 
ular fibrillation, the heart was excised, and thrombus mass 
within the left circumflex coronary artery was determined 
after removal by careful dissection. The heart was cut into 
1 cm thick transverse sections which were placed in 0.5% 
triphenyltetrazlium chloride in 0.01 M phosphate buffer 
(pH 7.4). Infarct size was quantitated gravimetrically with 
the aid of the differential histochemical reaction.“j 
Determination of serum potassium and digoxin con- 
centrations. Blood samples for the determination of 
serum digoxin and potassium concentrations were 
obtained by venipuncture 16 hours after the preceding 
administration of digoxin. Serum potassium concentra- 
tions were determined by flame photometry. Serum digox- 
in concentrations were determined by means of radioim- 
munoassay technique in the Ligand Assay Laboratory of 
the University of Michigan Medical School, with the use 
of sheep antidigoxin antiserum. 
Statistical analysis. For all evaluations, data are 
expressed as the mean ? S.E.M. Within a given treatment 
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Table I. Electrocardiographic and electrophysiologic responses* 
Digoxin Vehicle 
(n = 13) (n = 13) 
Parameter Before After Before After 
Heart rate (bpm) 109 * 5 115 f 7 100 t 7 102 * 6 
Mean arterial (mm Hg) pressure 79 t 4 79 i 7 78 + 3 84 i 5 
PR interval (msec) 118 f 3 120 + 4 123 2 4 125 i 5 
QRS interval (msec) 59 + 1 58 + 2 56 i 1 55 -i- 1 
QT, interval (msec)/(sec)!i 285 t 8 270 +- 5 265 -t 6 274 I 6 
Paced QT interval (msec) 205 k 7 189 + 5t 198 k 7 202 + 6 
Ventricular excitation threshold voltage (V)* 2.2 t 0.2 2.5 k 0.3 2.7 AI 0.6 3.5 It 0.8 
Ventricular refractory period (msecJ* 163 k 6 136 + 6$ 159 +- 7 140 + 5f 
*E:lectrophysiologic parameters determined at the right ventricular outflow tract site during programmed ventricular stimulation. 
tp < 0.05, $p < 0.01 before US after within the treatment group. 
Table II. Electrophysiologic responses in normal noninfarcted and infarcted zones of myocardium 
Digoxin Vehicle 
Site and parameter Before After Before After 
“Normal zone”* 
Excitation threshold (mA) 0.36 k 0.03 0.56 k 0.15 0.31 3T 0.07 0.53 f 0.22 
Relative refractory period (msec) 166 -t 7 146 + 3t 167 + 7 151 +- 6 
Effective refractory period (msec) 141 k 7 125 + 3t 139 + 5 126 k 12 
Activation time (msec) 20.5 zk 1.6 22.6 ? 1.9 20.7 t 2.0 19.8 f 2.0 
“Infarct zone”* 
Excitation threshold (mA) 0.48 k 0.07 0.90 + 0.26 0.30 + 0.04 0.49 I!z 0.09 
Relative refractory period (msec) 182 + 9 135 + 41011 179 + 7 153 t 4t 
Effective refractory period (msec) 152 +- 7 117 k 5t. 142 k 5 124 Y!Y 2t 
Activation time (msec) 24.2 t 2.2 22.1 k 2.3 20.5 f 1.6 19.2 -t 1.9 
*For all normal zone parameters, n = 13; infarct zone values for excitation threshold, relative and effective refractory periods are n = 9 and n = 8 for the 
digoxin and vehicle treatment groups, respectively. The reduction in n in the infarct zone was due to the inability to construct strength-interval curves in 
electrically inexcitable tissue in several animals. 
tp < 0.05, xp < 0.01 before us after within the treatment group and within the Same zone of myocardium. 
$p < 0.01 infarct zone post parameter OS paired normal zone post parameter within the same treatment group. 
lip < 0.05 digoxin post treatment parameter LIS analogous vehicle post treatment parameter within the same zone of myocardium. 
group, pre- us post treatment comparisons and normal 
zone us infarct zone comparisons were made using a 
two-tailed paired Student’s t test. Differences between the 
two treatment groups were analyzed by a two-tailed 
unpaired t test or by a Fisher’s exact test, when appropri- 
ate. For all comparisons, a p value of less than 0.05 was the 
criterion for statistical significance. 
RESULTS 
Twenty-six conscious post infarction dogs were 
entered into the present study. These animals were 
randomized to treatment with digoxin (n = 13; 
0.0125 mg/kg/day intravenously for a mean treat- 
ment period of 5.9 + 0.4 days), or with vehicle 
(n = 13; digoxin diluent administered in matching 
volume for a mean treatment period of 5.3 +- 0.4 
days). The pre- and post treatment responses of the 
post infarction dogs to electrophysiologic testing 
and programmed ventricular stimulation, as well as 
the responses of the treated animals to the subse- 
quent development of acute posterolateral ischemia, 
are presented below. 
Serum digoxin-Time course profile. Daily determi- 
nations of serum digoxin concentrations were per- 
formed for the first six digoxin-treated dogs com- 
pleting a 7-day treatment period. Serum samples for 
the digoxin assay were obtained by peripheral veni- 
puncture 16 hours after the preceding administra- 
tion of digoxin. After 4 to 7 days of treatment, serum 
digoxin concentrations ranging from 0.80 to 2.31 
rig/ml were achieved in these animals. Mean serum 
digoxin concentrations for treatment days 4 through 
7 for this group ranged from 1.12 + 0.30 to 1.40 f 
0.32 rig/ml (Fig. 2). All digoxin-treated dogs in this 
study were administered intravenous digoxin for 
treatment periods of 5 to 7 days before repeat 
programmed ventricular stimulation and electro- 
physiologic testing. 
Programmed electrical stimulation. Twenty-six post 
infarction dogs were subjected to repeat pro- 
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Table III. Response to ischemia at a site remote from 
previous myocardial infarction 
Parameter 
Time to ischemia (min) 
Increase in heart rate 
upon ST segment 
change (“(, of 
pre-ischemic rate) 




Infarct size (‘(, of left 
Digoxin Vehicle 
60- 
ffl = 10) (n = 12) 
298 * 33 219 * 35 




4 8 12 16 20 24 
6/10* 2112 
HOURS AFTER ISCHEMIA 
ventricle) 
Left anterior descending 
Left circumflex 
Thrombus mass 
6.6 k 1.4 
18.3 t 3.2 
(n = 6) 
12.2 -c .9 
6.3 + 1.8 
21.5 + 2.3 
13.4 r 3.2 
Fig. 3. Mortality rates of digoxin- and vehicle-pretreated 
post infarction dogs after the development of posterolat- 
era1 ischemia following left circumflex intimal injury. 
*p < 0.05 digoxin us vehicle treatment group. 
tIncidence of ventricular fibrillation within 60 minutes of &hernia. 
grammed ventricular stimulation in the conscious 
unsedated state after digoxin (n = 13) or vehicle 
(n = 13) treatment. Before treatment, all dogs had 
been determined noninducible during programmed 
stimulation testing. At the time of retesting, animals 
in the digoxin-treated group had a mean serum 
digoxin concentration of 1.36 +- 0.17 rig/ml, and all 
dogs in both groups appeared healthy and displayed 
no spontaneous ventricular ectopy. Repeat pro- 
grammed ventricular stimulation failed to initiate 
nonsustained or sustained ventricular tachycardia in 
12 of 13 digoxin-treated and in 13 of 13 vehicle- 
treated animals. One previously noninducible digox- 
in-treated dog responded to repeat programmed 
ventricular stimulation with a rapid polymorphic 
ventricular tachycardia that degenerated into ven- 
tricular fibrillation, and was not resuscitated. The 
sizes of the underlying anterior myocardial infarc- 
tions did not vary significantly between the digoxin- 
treated (7.1 + 1.4% of left ventricle) and vehicle- 
treated (6.3 f 1.6% of left ventricle) animals sub- 
jected to repeat programmed stimulation. 
Electrophysiologic responses. Table I summarizes 
the pre- and post treatment values for ECG inter- 
vals, sinus heart rate, mean arterial pressure, and for 
ventricular excitation threshold voltage and refrac- 
tory period, determined at the right ventricular 
outflow tract (RVOT) site during programmed ven- 
tricular stimulation. For both treatment groups, 
post treatment RVOT refractory periods were sig- 
nificantly less than their respective pretreatment 
values, with the reduction in refractoriness in the 
digoxin treatment group being greater in magnitude 
than that observed in the vehicle treatment group 
(Table I). Digoxin administration to post infarction 
dogs resulted in a significant reduction in the QT 
interval, while ECG intervals were unaltered in the 
vehicle group (Table I). 
Pre- and post treatment values for ventricular 
activation time, ET, RRP, and ERP, determined in 
NZs and IZs of myocardium, are presented in Table 
II. For both the digoxin and vehicle treatment 
groups, the NZ and IZ post treatment values for 
RRP and ERP were less than their appropriate 
pretreatment values. However, the reductions in 
relative and effective refractoriness for both nonin- 
farcted and infarcted myocardium were consistently 
greater in magnitude for the digoxin treatment 
group than for the vehicle treatment group (Table 
II). The most striking electrophysiological alteration 
observed in this evaluation was the reduction in the 
RRP value for infarcted myocardium in the digoxin 
treatment group. After digoxin administration, the 
RRP value in infarcted myocardium was significant- 
ly less than the post treatment RRP value in 
noninfarcted myocardium within the digoxin treat- 
ment group, and additionally was significantly less 
than the corresponding post treatment RRP value in 
infarcted myocardium in the vehicle treatment 
group (Table II). 
Response to ischemia at a site remote from previous 
myocardial infarction. Immediately after post treat- 
ment programmed ventricular stimulation, an anod- 
al current of 150 PA was applied to the intimal 
surface of the left circumflex coronary artery in each 
of 10 digoxin-treated and 12 vehicle-treated post 
infarction dogs. At the time of this procedure, the 
animals in the digoxin-treated group had a mean 
serum digoxin concentration of 1.47 +- 0.19 rig/ml. 
Serum potassium concentrations of digoxin-treated 
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LCX INTIMAL STIMULATION (150 uA ANODAL) - 
WGOXIN 0.0 125 MO/KG/DAY 
Fig. 4. Ventricular fibrillation in a digoxin-pretreated conscious dog in response to the development of 
posterolateral ischemia in the presence of anterior myocardial infarction. An anodal current of 150 PA was 
applied to the intimal surface of the left circumflex (LCX) coronary artery at time 0. In this experiment, 
ECG alterations reflecting acute ischemia (widened QRS with increasing R wave amplitude, reflex 
tachvcardial was observed at 257 minutes of current, and were followed rapidly by the development of 
ventricular fibrillation. Depicted ECG is lead II. 
(3.72 * 0.09 mEq/L) and vehicle-treated (3.66 rt 
0.15 mEq/L) dogs entering this phase of the evalua- 
tion were not significantly different. The responses 
of the two treatment groups to left circumflex 
intimal stimulation are summarized in Table III. 
The responses of digoxin- and vehicle-pretreated 
dogs to posterolateral ischemia in the presence of a 
previous anterior infarction are compared graphical- 
ly in the mortality curves depicted in Fig. 3. Within 
60 minutes of the onset of ischemia, 4 of 10 digoxin- 
treated dogs us 0 of 12 vehicle-treated dogs had 
developed ventricular fibrillation (40 % digoxin us 
0% vehicle; p < 0.05). The mean time to the devel- 
opment of ventricular fibrillation after the onset of 
ischemia in these four digoxin-treated dogs was 
5.3 + 0.4 minutes, and the serum digoxin concentra- 
tions for these four animals ranged from 0.82 to 1.32 
rig/ml. The incidence of arrhythmic fatalities at 24 
hours after the development of posterolateral ische- 
mia was 6 of 10 in the digoxin treatment group and 2 
of 12 in the vehicle treatment group (60% digoxin us 
17% vehicle; p < 0.05), with two “late” arrhythmic 
deaths occurring in each of the two groups. Fig. 4 
illustrates the development of ventricular fibrilla- 
tion shortly after the development of posterolateral 
ischemia in a digoxin-treated post infarction dog. 
DISCUSSION 
Previous clinical studies. The use of digitalis after 
myocardial infarction remains controversial, due 
primarily to an uncertainty regarding the arrhyth- 
mogenic potential of digitalis in the setting of is- 
chemic myocardial injury.‘** Initial clinical investi- 
gations have not provided unequivocal evidence of 
an increased incidence of ventricular arrhythmias 
after the administration of digitalis in the post 
infarction period, but have been characterized large- 
ly as anecdotal, poorly designed, and/or lacking 
appropriate control groups, and ultimately unper- 
suasive.1g~20 In one clinical trial involving 54 patients 
studied within 48 hours of admission for myocardial 
infarction, Lown et a1.21 demonstrated that 48 
patients (89 % of total) could tolerate the single dose 
acute intravenous administration of 1.0 mg of acetyl 
strophanthidin without displaying deleterious con- 
duction disturbances or spontaneous arrhythmias 
during or up to 30 minutes following drug infusion. 
Reicansky et a1.,22 in a randomized, double-blinded 
study, found no differences in the incidences of 
ventricular arrhythmias during monitoring periods 1 
hour before and up to 3 hours after the single dose 
acute intravenous administration of 0.1 mg/kg 
digoxin (18 patients) or saline vehicle (15 patients). 
Recently, several large retrospective clinical studies 
have employed multivariate statistical techniques in 
an attempt to identify potential deleterious effects 
of chronic digitalis therapy on survival after myocar- 
dial infarction.3-7 Moss et a1.3 and Bigger et al.” have 
reported statistically significant associations be- 
tween digitalis therapy and mortality at 4 months 
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and 1 year after infarction, respectively, in patients 
with left ventricular failure and ventricular arrhyth- 
mias. In contrast to the preceding reports, Ryan et 
a1.5 and Madsen et a1.6 failed to detect a significant, 
independent association between digitalis therapy 
and post infarction mortality, although the exclu- 
sion of early post infarction deaths in the former 
study5 may have influenced this relationship. Bigger 
and associates7 recently have extended their post 
infarction patient evaluation throughout a 3-year 
follow-up period, and have reported the indepen- 
dent association between digitalis therapy and post 
infarction mortality to be of borderline statistical 
significance (0.05 < p < 0.10). Additionally, digitalis 
therapy recently has been identified as a significant 
independent predictor of mortality in a patient 
group consisting of resuscitated victims of cardiac 
arrest.23 
Previous experimental studies. Experimental stud- 
ies conducted to date consistently suggest an 
enhanced myocardial sensitivity to the toxic effects 
of digitalis preparations during myocardial ischemia 
and after myocardial infarction. Early studies dem- 
onstrated a significant reduction in the intravenous 
lethal threshold dosage of tincture of digitalis 
infused subacute19 or chronicall+ l1 after myocardi- 
al infarction in dogs and cats. More recent investiga- 
tors have demonstrated significant reductions in the 
intravenous and/or intracoronary arrhythmogenic 
threshold dosages of digitalis preparations (acetyl 
strophanthidin or ouabain) infused during myocar- 
dial ischemia,g~‘o acutely after the reperfusion of an 
occluded coronary artery,l’ and at several days,12, l3 1 
month,14 and 3 months15 after myocardial infarction 
in pigs and dogs. However, the clinical relevance of 
these findings has been questioned because of the 
consistent use of acute rapid administrations of 
clearly supratherapeutic and toxic concentrations of 
the digitalis preparations in assessing myocardial 
sensitivity in the setting of ischemic myocardial 
injury.21 
Present findings: The facilitation of lethal ventricular 
arrhythmias by therapeutic digoxin in conscious post 
infarction dogs. In the present study, conscious dogs 
in the subacute phase of myocardial infarction were 
used to evaluate the proarrhythmic potential of 
therapeutically-administered digoxin. The adminis- 
tration of digoxin to post infarction dogs (0.0125 
mg/kg/day intravenously for 5 to 7 consecutive days) 
yielded trough serum digoxin concentrations of 
1.36 k 0.17 and 1.47 + 0.19 rig/ml in animals sub- 
jected to repeat programmed stimulation and left 
circumflex coronary artery intimal injury, respec- 
tively. These serum digoxin concentrations compare 
favorably to the reported clinically therapeutic and 
nontoxic range of 0.8 to 1.6 rig/ml serum digox- 
in 24,25 
Digoxin-treated post infarction dogs in this study 
had a significantly greater 24-hour mortality rate 
after the development of ischemia at a site distant to 
the area of previous myocardial infarction, as com- 
pared to the vehicle-treated post infarction dogs. 
This enhanced mortality was due to a significantly 
enhanced vulnerability of the digoxin-treated ani- 
mals toward the sudden development of ventricular 
fibrillation in response to the acute ischemic epi- 
sode. Programmed ventricular stimulation testing 
before the development of posterolateral ischemia 
failed to predict this enhanced susceptibility of 
digoxin-treated post infarction dogs to the develop- 
ment of ischemia-induced lethal arrhythmias, sug- 
gesting that the proarrhythmic actions of digitalis 
may be mediated via an alteration in the electro- 
physiologic response of the infarcted heart to a new 
ischemic insult, rather than solely via an effect on 
the infarcted myocardial substrate. Electrophysio- 
logic measurements conducted during this study 
detected decreases in myocardial refractoriness and 
excitability after both digoxin and vehicle treat- 
ments, undoubtedly reflecting an evolving electro- 
physiologic “healing” process after the experimental 
myocardial infarction. However, the enhanced 
reduction in myocardial refractoriness observed in 
the digoxin group, particularly in the infarcted 
myocardium, as well as the reduction in QT interval 
(an ECG index for ventricular action potential dura- 
tion, which in turn is a primary determinant for 
cellular refractoriness), are consistent with the cellu- 
lar electrophysiologic actions of digitalis. Through 
an inhibition in Na+/K+-ATPase activity, digitalis is 
thought to cause an elevation in intracellular calci- 
um (Ca2+int) concentration that in turn augments a 
Ca’+i,,-dependent outward K+ conductance. This in 
turn is responsible for the observed acceleration in 
cardiac cell (phase 3) repolarization, a reduction in 
cardiac action potential duration, and therefore 
reduced cellular refractoriness.26 Future studies will 
be required to determine more fully the significance 
of this enhanced reduction in myocardial refractori- 
ness with regard to the increased susceptibility of 
digitalis-treated post infarction dogs to ischemia- 
induced ventricular arrhythmias. 
Conclusions. In conscious dogs in the subacute 
phase of anterior myocardial infarction, the admin- 
istration of digoxin in a therapeutic dosage regimen 
resulted in a significantly increased incidence in the 
development of lethal ventricular arrhythmias in 
response to ischemia at a site distant to the area of 
previous myocardial infarction. This enhanced sus- 
ceptibility of digoxin-treated post infarction dogs to 
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the development of ischemia-induced lethal 
arrhythmias was not predicted by programmed ven- 
tricular stimulation testing, and may involve a 
digoxin-mediated alteration in myocardial refracto- 
riness, particularly in the infarcted myocardium. 
These experimental findings support clinical obser- 
vations that digitalis therapy may constitute an 
independent risk factor contributing significantly to 
mortality after myocardial infarction. 
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